This is the authors' abstract. We don't add key points for this paper.
Chimeric antigen receptor (CAR) T-cell therapy is a novel therapy that uses either gamma-retroviral or lentiviral vectors to genetically modify a patient's autologous T cells to express an anti-CD19 antibody against CD19 + B-cell malignancies.1,2 Since 2017, a total of 3 anti-CD19 CAR T-cell therapies, axicabtagene ciloleucel (axi-cel; Yescarta), tisagenlecleucel (tisa-cel; Kymriah), and lisocabtagene maraleucel (liso-cel; Breyanzi), have been approved by the FDA and have demonstrated remarkable efficacy in the treatment of relapsed and refractory B-cell non-Hodgkin lymphomas (NHLs).[3][4][5][6][7][8] Initial long-term follow-up of these pivotal clinical trials showed low rates of myelodysplastic syndrome (MDS) after CAR T-cell therapy and no other subsequent malignant neoplasms (SMNs).9,10 However, multiple realworld retrospective analyses examining outcomes after treatment with CAR T-cell therapy report varying rates of SMNs ranging from 0.9% to 12.9%, with the most common being MDS.[8][9][10][11][12] These real-world studies are limited by small patient populations and often focus on the rate of treatment-related myeloid neoplasms, with limited data regarding solid tumor or other hematologic malignancies.On the 28th of November, 2023, the Food and Drug Administration (FDA) announced an investigation into reports of Tcell malignancies, including CAR-positive lymphomas, in patients who received treatment with B-cell maturation antigen (BCMA)-or CD19-directed autologous CAR T-cell immunotherapies.13,14 These findings raise concern for an increased rate of secondary T-cell neoplasms related to potential insertional mutagenesis from genetically modified CAR T-cell therapy.15,16 In light of the recent announcement by the FDA of reported cases of CAR-positive T-cell lymphomas after CAR T-cell therapy, we performed a large retrospective analysis examining the rates of SMNs in patients previously treated with anti-CD19 CAR Tcell therapy, with particular attention to the incidence of T-cell neoplasms.We identified 582 patients with relapsed and refractory large B-cell lymphoma (LBCL) treated with CAR T-cell therapy between 2015 and 2022 across 13 academic medical centers.Patients in this cohort received a median of 3 prior lines of therapy (range, 1-18), including 224 patients previously treated with autologous hematopoietic stem cell transplant (HSCT) and 6 patients who previously received an allogeneic-HSCT.Median follow-up in survivors was 35.3 months, with a median progression-free survival (PFS) of 11.5 months (95% confidence interval [CI], 6.08-16.92)and median overall survival (OS) of 27.8 months (95% CI, 21.2-34.5).Seventeen patients had Epstein-Barr virus (EBV) positive disease, 4 had HIV infection, and 26 patients had a previously diagnosed autoimmune condition (Table 1).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Melody et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: